SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is currently a focal point for investors debating the stock's future amid intense technical volatility and mixed signals regarding its long-term growth versus aggressive share dilution. While some community members highlight its expanding backlog, acquisition strategy, and defense sector partnerships, others are concerned by repeated price pullbacks and are closely monitoring the company's ability to capitalize on its recent strategic positioning.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is currently trending as investors debate the impact of its manufacturing joint venture with Toyota, with the community split between those viewing the partnership as a scaling moat and those concerned by ongoing stock volatility and dilution. Bulls emphasize the firm's progress in FAA flight testing and infrastructure development, while bears continue to highlight high cash burn and the speculative nature of the eVTOL industry.

Block, Inc. engages in creating ecosystems for distinct customer audiences. It operates through the following segments: Square and Cash App. The Square segment provides payment services, software solutions, hardware, and financial services to sellers. The Cash App segment includes the financial tools available to individuals within the mobile Cash App, including peer-to-peer payments, bitcoin and stock investments. The company was founded by Jack Patrick Dorsey and James Morgan McKelvey in February 2009 and is headquartered in Oakland, CA.

Block Inc - Ordinary Shares - Class A

Block Inc

Block Inc. is surging following a major restructuring plan that includes cutting 40% of its workforce as the company pivots toward an AI-native operational model. The community is actively debating the implications of using AI to drive margin expansion versus the potential long-term risks of mass layoffs and reduced human capital.

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.

Nuvation Bio Inc - Ordinary Shares - Class A

Nuvation Bio Inc. (NUVB) is drawing significant market attention as it transitions into a commercial-stage oncology company, with community focus centering on the commercial launch of its flagship drug, Ibtrozi, and strategic pipeline developments. Investors are actively debating the company's long-term valuation in light of recent financing moves and persistent buyout speculation, while closely monitoring how the firm's best-in-class pipeline candidates compete within the evolving oncology landscape.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as investors debate the impact of its newly launched proprietary prediction market exchange, DKeX, against competitive pressures from broader market entrants. While the community is split between bullish sentiment regarding the company's long-term dominance in the prediction space and frustration over recent stock volatility, active discussions remain heavily focused on how these predictive offerings will integrate with existing sportsbook operations and influence future revenue growth.

McDonald's Corp. engages in the operation and franchising of restaurants. The firm operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. Its products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, and McCafe beverages. The company was founded by Raymond Albert Kroc on April 15, 1955 and is headquartered in Chicago, IL.

McDonald`s Corp

McDonald's Corp

McDonald's is under significant pressure as investors navigate concerns over shifting consumer habits, the rise of GLP-1 weight-loss drugs, and softening same-store sales. While some traders view the stock as a defensive value play and an opportunity for long-term accumulation near key support levels, the broader community remains divided, with active discussions focusing on technical breakdown risks and the effectiveness of management's turnaround strategies.

Riot Platforms, Inc. is a bitcoin mining company, which engages in the provision of special cryptocurrency mining computers. It invests in Verady, Coinsquare, and Tess. It operates through the Bitcoin Mining and Engineering segments. The Bitcoin Mining segment focuses on maximizing ability to successfully mine Bitcoin by growing hash rate. The Engineering segment designs and manufactures power distribution equipment and custom engineered electrical products that provides them the ability to vertically integrate many of the critical electrical components and engineering service. The company was founded on July 24, 2000 and is headquartered in Castle Rock, CO.

Riot Platforms Inc

Riot Platforms is seeing intense volatility as the community debates its pivot from Bitcoin mining to high-performance AI data center infrastructure. Investors are sharply divided, with some expressing frustration over recent price fluctuations and manipulative trading patterns, while others remain bullish on the long-term potential of the firm's power capacity and institutional partnerships.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending as investors monitor the commercial launch of NEREUS for motion sickness and engage in active speculation regarding potential buyout interest from major pharmaceutical players. While the community remains focused on the company's pipeline developments and GLP-1 adjunct opportunities, ongoing discussions are fueled by frustration over persistent price volatility and the company's aggressive regulatory strategy.

Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. It uses antibody discovery and protein engineering to create new therapies. The company is advancing late-stage IGF-1R therapies for thyroid eye disease (TED) and developing a potential TSHR-targeted treatment for TED and Graves’ disease. In addition, it is developing FcRn inhibitors, including VRDN-006 and VRDN-008, for multiple autoimmune diseases. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Viridian Therapeutics Inc

Viridian Therapeutics is trending due to the recent FDA approval of its thyroid eye disease treatment, Lumvoa, which is uniquely labeled for both active and chronic disease. The community is actively discussing the drug's potential to capture significant market share from existing competitors and monitoring the company's immediate commercial launch plans.

Direxion Shares ETF Trust - Direxion Daily FTSE China Bull 3X ETF

Direxion Daily FTSE China Bull 3X Shares

YINN is experiencing heightened volatility as investors weigh conflicting sentiments regarding the Chinese economy, with some bulls highlighting deep value and stimulus potential while bears point to persistent macroeconomic pressures. The community remains sharply divided, with active debates focused on whether recent price action represents a sustainable rebound or a classic trap driven by speculative trading.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Average Recommendation of "Buy" by Brokerages

Inhibikase Therapeutics, Inc. (NASDAQ:IKT - Get Free Report) has been assigned a consensus recommendation of "Buy" from the eight ratings firms that are covering the company, Marketbeat reports. One...

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Rating of "Buy" by Analysts

Shares of Inhibikase Therapeutics, Inc. (NASDAQ:IKT - Get Free Report) have earned an average rating of "Buy" from the eight analysts that are presently covering the company, MarketBeat reports. One...

HC Wainwright Issues Positive Estimate for IKT Earnings

Inhibikase Therapeutics, Inc. (NASDAQ:IKT - Free Report) - Equities researchers at HC Wainwright increased their Q1 2026 earnings per share estimates for Inhibikase Therapeutics in a research report...

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Average Rating of "Buy" by Analysts

Inhibikase Therapeutics, Inc. (NASDAQ:IKT - Get Free Report) has received a consensus recommendation of "Buy" from the six ratings firms that are presently covering the firm, Marketbeat Ratings...

Inhibikase Therapeutics (NASDAQ:IKT) Upgraded to "Strong-Buy" at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH upgraded Inhibikase Therapeutics to a "strong-buy" rating in a report on Wednesday...

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Short Interest Update

Inhibikase Therapeutics, Inc. (NASDAQ:IKT - Get Free Report) was the recipient of a large growth in short interest during the month of February. As of February 13th, there was short interest totaling...

Inhibikase Therapeutics (NYSE:IKT) Coverage Initiated at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH initiated coverage on Inhibikase Therapeutics in a research report on Wednesday. They set a "buy" rating and a $4.00 target price for the company...

FY2025 Earnings Forecast for IKT Issued By Lifesci Capital

Inhibikase Therapeutics, Inc. (NYSE:IKT - Free Report) - Stock analysts at Lifesci Capital issued their FY2025 earnings per share estimates for Inhibikase Therapeutics in a report issued on Monday...

Inhibikase Therapeutics (NYSE:IKT) Trading Up 4.4% - Still a Buy?

Inhibikase Therapeutics (NYSE:IKT) Stock Price Up 4.4% - Time to Buy...

Inhibikase Therapeutics (NASDAQ:IKT) Upgraded by Lifesci Capital to "Strong-Buy" Rating

Lifesci Capital raised Inhibikase Therapeutics to a "strong-buy" rating in a report on Monday...

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in development of protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. It also focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. The company was founded by Milton H. Werner in September 2008 and is headquartered in Wilmington, DE.

Inhibikase Therapeutics Inc

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

IKTInhibikase Therapeutics Inc

Fundamentals

Latest IKT News